yttrium-90-DTPA-cT84.66

yttrium-90-DTPA-cT84.66 is a radioimmunoconjugate composed of the chimeric monoclonal antibody cT84.66, which targets human carcinoembryonic antigen (CEA), conjugated to the chelating agent diethylenetriaminepentaacetic acid (DTPA) and radiolabeled with the beta-emitting isotope yttrium-90 (Y‑90). The drug is designed for radioimmunotherapy, delivering targeted radiation to CEA-expressing tumor cells in patients with metastatic or advanced malignancies that produce CEA, such as colorectal cancer and other solid tumors[1][2][4]. The mechanism of action involves specific binding of the antibody to CEA on tumor cells, allowing localized delivery of cytotoxic radiation from Y‑90, thereby minimizing damage to surrounding healthy tissue[2][3]. Clinical studies have demonstrated dose-limiting hematologic toxicity and immunogenicity (human anti-chimeric antibody response) as primary safety concerns[1][5]. Developed at Beckman Research Institute of City of Hope, this investigational therapy has been evaluated in phase I/II trials for neoplasms expressing CEA[3][4].

Other names

yttrium Y 90 anti-CEA monoclonal antibody cT84.6690Y-cT84.66